Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer

NCT02643667 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02643667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02643667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
April 12, 2023
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer